Department of Anesthesiology, Washington University, St Louis, USA.
BMC Anesthesiol. 2009 Nov 30;9:8. doi: 10.1186/1471-2253-9-8.
Awareness with explicit recall of intra-operative events is a rare and distressing complication that may lead to severe psychological symptoms. Candidate depth of anesthesia monitors have been developed, partly with the aim of preventing this complication. Despite conflicting results from clinical trials and the lack of incisive validation, such monitors have enjoyed widespread clinical adoption, in particular the bispectral index. The American Society of Anesthesiologists has called for adequately powered and rigorously designed clinical trials to determine whether the use of such monitors decreases the incidence of awareness in various settings. The aim of this study is to determine with increased precision whether incorporating the bispectral index into a structured general anesthesia protocol decreases the incidence of awareness with explicit recall among a subset of surgical patients at increased risk for awareness and scheduled to receive an inhalation gas-based general anesthetic.
METHODS/DESIGN: BAG-RECALL is a multi-center, randomized, controlled clinical trial, in which 6,000 patients are being assigned to bispectral index-guided anesthesia (target range, 40 to 60) or end-tidal anesthetic gas-guided anesthesia (target range, 0.7 to 1.3 age-adjusted minimum alveolar concentration). Postoperatively, patients are being assessed for explicit recall at two intervals (0 to 72 hours, and 30 days after extubation). The primary outcome of the trial is awareness with explicit recall. Secondary outcomes include postoperative mortality, psychological symptoms, intensive care and hospital length of stay, average anesthetic gas administration, postoperative pain and nausea and vomiting, duration of stay in the recovery area, intra-operative dreaming, and postoperative delirium.
This trial has been designed to complement two other clinical trials: B-Unaware and MACS (ClinicalTrials.gov numbers, NCT00281489 and NCT00689091). With the large patient numbers and complementary rigorous designs, it is envisaged that pre-specified meta-analyses will address some of the outstanding controversies and questions relating to processed electroencephalography monitoring.
ClinicalTrials.gov Identifier: NCT00682825.
术中事件的明确回忆意识是一种罕见且令人痛苦的并发症,可能导致严重的心理症状。候选深度麻醉监测仪已经开发出来,部分目的是预防这种并发症。尽管临床试验结果存在冲突,并且缺乏有说服力的验证,但此类监测仪仍已广泛应用于临床,特别是双频谱指数。美国麻醉医师协会呼吁进行充分有力且精心设计的临床试验,以确定此类监测仪的使用是否会降低各种情况下的意识发生率。本研究的目的是更精确地确定将双频谱指数纳入结构化全身麻醉方案是否会降低具有明确回忆的高危意识患者子集的发生率,并计划接受吸入气体全身麻醉。
方法/设计:BAG-RECALL 是一项多中心、随机、对照临床试验,其中 6000 名患者被分配到双频谱指数指导的麻醉(目标范围为 40 至 60)或呼气末麻醉气体指导的麻醉(目标范围为 0.7 至 1.3 年龄调整的最低肺泡浓度)。术后,患者在两个时间间隔(0 至 72 小时和拔管后 30 天)进行明确回忆评估。试验的主要结局是明确回忆的意识。次要结局包括术后死亡率、心理症状、重症监护和住院时间、平均麻醉气体给药、术后疼痛和恶心呕吐、恢复区停留时间、术中做梦和术后谵妄。
本试验旨在补充两项其他临床试验:B-Unaware 和 MACS(ClinicalTrials.gov 编号:NCT00281489 和 NCT00689091)。通过大量患者和互补的严格设计,预计预先指定的荟萃分析将解决一些与处理脑电图监测相关的未决争议和问题。
ClinicalTrials.gov 标识符:NCT00682825。